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A BS T R AC T
Background

In this randomized clinical trial, we aimed to determine whether increasing the
frequency of in-center hemodialysis would result in beneficial changes in left ventricular mass, self-reported physical health, and other intermediate outcomes among
patients undergoing maintenance hemodialysis.
Methods

Patients were randomly assigned to undergo hemodialysis six times per week (frequent
hemodialysis, 125 patients) or three times per week (conventional hemodialysis, 120
patients) for 12 months. The two coprimary composite outcomes were death or
change (from baseline to 12 months) in left ventricular mass, as assessed by cardiac
magnetic resonance imaging, and death or change in the physical-health composite
score of the RAND 36-item health survey. Secondary outcomes included cognitive
performance; self-reported depression; laboratory markers of nutrition, mineral metabolism, and anemia; blood pressure; and rates of hospitalization and of interventions related to vascular access.
Results

Patients in the frequent-hemodialysis group averaged 5.2 sessions per week; the weekly standard Kt/Vurea (the product of the urea clearance and the duration of the dialysis
session normalized to the volume of distribution of urea) was significantly higher in the
frequent-hemodialysis group than in the conventional-hemodialysis group (3.54±0.56
vs. 2.49±0.27). Frequent hemodialysis was associated with significant benefits with
respect to both coprimary composite outcomes (hazard ratio for death or increase in
left ventricular mass, 0.61; 95% confidence interval [CI], 0.46 to 0.82; hazard ratio for
death or a decrease in the physical-health composite score, 0.70; 95% CI, 0.53 to 0.92).
Patients randomly assigned to frequent hemodialysis were more likely to undergo
interventions related to vascular access than were patients assigned to conventional
hemodialysis (hazard ratio, 1.71; 95% CI, 1.08 to 2.73). Frequent hemodialysis was
associated with improved control of hypertension and hyperphosphatemia. There were
no significant effects of frequent hemodialysis on cognitive performance, self-reported
depression, serum albumin concentration, or use of erythropoiesis-stimulating agents.
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Conclusions

Frequent hemodialysis, as compared with conventional hemodialysis, was associated with favorable results with respect to the composite outcomes of death or
change in left ventricular mass and death or change in a physical-health composite
score but prompted more frequent interventions related to vascular access. (Funded
by the National Institute of Diabetes and Digestive and Kidney Diseases and others;
ClinicalTrials.gov number, NCT00264758.)
n engl j med 363;24

nejm.org

december 9, 2010

2287

The New England Journal of Medicine
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on July 29, 2014. For personal use only. No other uses without permission.
Copyright © 2010 Massachusetts Medical Society. All rights reserved.

The

n e w e ng l a n d j o u r na l

W

hen 90% or more of usual kidney
function is lost, either kidney transplantation or dialysis is required to sustain
life. Nearly 400,000 persons in the United States
and 2 million worldwide are dependent on dialysis; of these, approximately 90% in the United
States and 70% in Canada undergo hemodialysis,
which is typically delivered three times a week.1
The rationale for thrice-weekly hemodialysis was
derived from a combination of physiological experiments, assessments of patient acceptance,
feasibility, logistics, and costs.2-4 Mortality remains high (approximately 18 to 20% per year)
despite improvements in the technology for dialysis, the development of new pharmaceutical
agents, and experience over the course of more
than 40 years since maintenance dialysis became
available. Moreover, although dialysis can sustain
life, it rarely restores health; patients undergoing
dialysis have considerable complications (including frequent and extended hospitalizations)1 and
relatively poor functional status and health-related
quality of life.5-7
The optimal “dose” of hemodialysis remains
uncertain. Anchored to a thrice-weekly regimen
and typically expressed as a metric of smallsolute (urea) clearance, dialysis dosing has been
informed by numerous observational studies8-10
and a few carefully conducted, randomized clinical trials.11,12 Despite ample observational data
suggesting that the dose of hemodialysis (expressed as the per-session Kt/Vurea, which is the
product of the urea clearance and the duration of
the dialysis session normalized to the volume
of distribution of urea) correlates directly with
survival, the Hemodialysis (HEMO) Study showed
that there was no benefit from more intensive
hemodialysis (higher per-session Kt/Vurea) when
patients underwent hemodialysis three times a
week.12 However, solute removal can be dramatically augmented by increasing the frequency of
hemodialysis sessions.13 Several uncontrolled
studies showed that there were significant improvements in patient-reported outcomes and results of laboratory tests when patients were treated
with more frequent in-center or at-home hemodialysis.14,15 Because of ongoing uncertainty regarding the optimal dose of hemodialysis, we
tested the hypothesis that frequent (six times per
week) in-center hemodialysis, as compared with
conventional thrice-weekly hemodialysis, would
improve an array of objective and patient-reported
outcomes.
2288
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Me thods
Study Protocol

The Frequent Hemodialysis Network (FHN) Daily
Trial was a multicenter, prospective, randomized,
parallel-group trial of frequent (six times per
week), as compared with conventional (three times
per week) in-center hemodialysis. The study was
conducted between January 2006 and March
2010 at 11 university-based and 54 communitybased hemodialysis facilities in North America
(for a list of participating sites, see the Supplementary Appendix, available with the full text of
this article at NEJM.org). The design of the FHN
Daily Trial has been described previously.16
The FHN Daily Trial and a companion Nocturnal Trial (ClinicalTrials.gov number, NCT00271999)
were sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases and the
Centers for Medicare and Medicaid Services, with
additional support from DaVita, Dialysis Clinics,
Fresenius Medical Care, Renal Advantage, Renal
Research Institute, and Satellite Healthcare. The
dialysis companies donated several weekly dialysis sessions; they had no role in the design of the
study or in the analysis of the data. Recruitment
and data collection were performed by site investigators and study coordinators. An independent
data and safety monitoring board reviewed the
safety data and interim results. The study was
approved by the institutional review board at each
participating study site. The protocol for the study,
including the statistical analysis plan, is available
at NEJM.org. The authors attest to the fidelity of
this report to the trial protocol.
Study Population

Specific inclusion and exclusion criteria are listed
in Table 1 in the Supplementary Appendix. Written
informed consent was obtained from all patients
18 years of age or older; patient assent and written parental consent were obtained from participants younger than 18 years of age.
Study Design

Randomization

Randomization was stratified according to clinical center and diabetes status, with the use of
randomly permuted blocks. Although treatment
assignments could not be concealed, betweengroup comparisons of the outcomes were concealed from the investigators throughout the
course of the trial.
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Intervention

Outcomes

After randomization, prescriptions for dialysis
were determined centrally and were transmitted
to each clinical center. Patients who were assigned
to thrice-weekly hemodialysis (120 patients) continued their usual dialysis prescriptions, which included a minimum target equilibrated Kt/Vurea of
1.1 and a session length of 2.5 to 4.0 hours. The
equilibrated Kt/Vurea is the ratio of the equilibrated
urea clearance during each dialysis session (Kt) to
the patient’s volume of urea distribution (V).17 The
target equilibrated Kt/Vn, where Vn = 3.271 × V2/3,
in the group that underwent hemodialysis six
times per week (125 patients) was 0.9 provided
that the length of the session was between 1.5
and 2.75 hours. These prescriptions were factored
by V2/3 rather than V (similar to scaling surface
area from body mass) to reduce the dependence
of dialysis prescriptions on body mass and to
avoid unfeasibly long dialysis treatments for patients with large body mass. Simulation studies
indicated that these interventions would provide
substantial differences in targeted weekly standard Kt/Vurea between the treatment groups.

It was not feasible to recruit a sample large enough
to provide adequate statistical power to assess
individual end points of death, cause-specific
death, hospitalization, or other events. Therefore,
we selected two composite coprimary outcomes:
death or 12-month change in left ventricular
mass, as assessed by cardiac MRI, and death or
12-month change in the physical-health composite score from the RAND 36-item health survey
(RAND-36).20 We determined that favorable effects on both coprimary outcomes would be required to provide evidence of overall benefit. We
selected nine domains for secondary analysis;
within eight of those domains, we selected a main
secondary outcome: for the domain of cardiovascular structure and function, the outcome was
left ventricular mass; for the domain of physical
health, the outcome was the physical-health composite score of the RAND-36; for the domain of
mental health, the outcome was the score on the
Beck Depression Inventory; for the domain of
cognitive function, the outcome was the score
on the Trail Making Test, Part B; for the domain
of nutrition, the outcome was the serum albumin
concentration before dialysis; for the domain of
mineral metabolism, the outcome was the serum
phosphorus concentration before dialysis; for the
domain of anemia, the outcome was the dose of
an erythropoiesis-stimulating agent; and for the
domain of death and hospitalization, the outcome
was the rate of the composite of death or the first
hospitalization unrelated to vascular access. For
the ninth domain, hypertension, we specified two
main secondary outcomes: systolic blood pressure before dialysis and the number of antihypertensive agents the patient was taking. We focused
on several potential risks, including the need for
interventions related to vascular access. Deaths,
hospitalizations, and complications related to vascular access were adjudicated by an outcomes
committee whose members were unaware of the
patients’ intervention assignment. Complications
related to vascular access were defined as access
failure, infection requiring a procedure, thrombectomy, angioplasty, and fibrin stripping of catheters or replacement of catheters.

Other Measurements

We obtained data on demographic characteristics
at baseline, with clinical data and laboratory-test
results obtained at baseline and serially over the
course of the study. We calculated adherence as
the ratio of outpatient dialysis sessions attended
to outpatient dialysis sessions prescribed, by
month. We obtained standardized assessments
of coexisting conditions with the use of a modified version of the Charlson Comorbidity Index18
supplemented with additional items from the Index of Coexistent Diseases.19 Questionnaires were
administered by telephone in either English or
Spanish through a centralized call center; personnel administering the questionnaire were unaware of the participants’ intervention assignment. Cardiac magnetic resonance imaging (MRI)
was performed with the use of a standardized
protocol; images were analyzed in a blinded
fashion at a central core laboratory. A committee
overseeing standards of care periodically reviewed
and reported to the clinical centers the results of
prespecified measures (serum phosphate and bicarbonate and blood hemoglobin concentrations;
normalized protein nitrogen appearance; and
blood pressure relative to the achieved target
weight after dialysis) that were outside the ranges
recommended in published guidelines.
n engl j med 363;24

Statistical Analysis

We used the Hochberg modification of the Bonferroni procedure to provide a studywide two-sided
significance level approximating 0.05 when considering the two coprimary composite outcomes.21
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of the RAND-36 (in which scores range from 0 to
100 and higher scores indicate better physical
status) of 4.6 to 5.0 points, with the detectable
effect on each coprimary outcome varying slightly depending on the size of the treatment effect
on the other coprimary end point.

Table 1. Baseline Characteristics of the Study Participants.*

Characteristic
Age (yr)
Female sex (%)

Conventional
Hemodialysis
(N = 120)

Frequent
Hemodialysis
(N = 125)

52.0±14.1

48.9±13.6

0.07

39.2

37.6

0.80

Race or ethnic group (%)†

P Value

0.32

Black

44.2

39.2

White

38.3

34.4

3.3

3.2

Native American, Aboriginal Canadian, Alaskan Native,
or First Nation
Asian

4.2

8.8

Native Hawaiian or other Pacific Islander

2.5

0.8

Other or mixed

7.5

13.6

Body-mass index‡

27.5±7.1

27.3±6.5

0.82

Weight after dialysis (kg)

78.7±20.5

77.6±20.6

0.68

Anthropometric volume (liters)§

39.5±8.3

39.3±8.1

0.90

Cause of end-stage renal disease (%)

0.89

Diabetic nephropathy

32.5

36.0

Glomerulonephritis

19.2

19.2

Hypertensive nephrosclerosis

20.0

21.6

5.0

3.2

23.3

20.0

16.7

16.0

Polycystic kidney disease
Other
Duration of end-stage renal disease (%)

0.38

<2 yr
2–5 yr

42.5

35.2

>5 yr

40.8

48.8

Hypertension

87.3

91.5

0.12

Myocardial infarction

13.3

8.8

0.26

Heart failure

20.0

20.0

1.00

Coexisting medical conditions (%)

Atrial fibrillation

7.5

4.0

0.24

Peripheral arterial disease

8.3

12.0

0.34

Abdominal aortic aneurysm repair or bypass grafting

1.7

2.4

0.68
0.93

Stroke

7.5

7.2

Dementia

0.8

0.0

0.31

Tumor without metastases

6.7

1.6

0.04

Diabetes and complications of diabetes

2290

41.7

40.0

0.79

Hemiplegia

0.8

1.6

0.59

Chronic pulmonary disease

4.2

4.8

0.81

Moderate or severe liver disease

0.8

0.8

0.98
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Table 1. (Continued.)
Conventional
Hemodialysis
(N = 120)

Frequent
Hemodialysis
(N = 125)

Anuria

60.0

72.0

>0 to 1 ml/min

15.8

14.4

Characteristic
Residual kidney function (%)

P Value
0.17

24.2

13.6

Diastolic blood pressure before dialysis (mm Hg)

>1 to 3 ml/min

78.4±11.7

81.0±11.2

0.08

Serum creatinine (mg/dl)¶

10.3±2.5

10.8±3.0

0.21

Weekly standard

2.54±0.39

2.50±0.31

0.45

Equilibrated

1.43±0.28

1.43±0.25

0.94

Fistula

62.5

65.6

Synthetic graft

18.3

16.0

Catheter

19.2

18.4

Kt/Vurea‖

Dialysis access (%)**

0.86

*		
†		
‡		
§		
¶		
‖		

Plus–minus values are means ±SD.
Race or ethnic group was self-reported.
The body-mass index is the weight in kilograms divided by the square of the height in meters.
Anthropometric volume was calculated with the use of the Watson equation.
To convert the values for creatinine to micromoles per liter, multiply by 88.4.
The weekly standard Kt/Vurea is defined as the ratio of the generation rate of urea to the average urea concentration before dialysis and is commonly used to compare small-molecule clearance among different methods and schedules of dialysis.22 The equilibrated Kt/V (the ratio of the equilibrated urea clearance during each dialysis session [Kt] to the patient’s urea distribution volume [V]) is computed with the use of a modified Tattersall correction to single-pool Kt/V.17
** The proportions of upper arm and forearm fistulas were 47% and 52%, respectively; the proportions of upper arm
and forearm grafts were 62% and 29%, respectively.

The analysis of the coprimary composite outcomes was performed with the use of a rankbased procedure, as follows: patients who died
before 12 months were ranked from lowest (indicating the poorest outcome) to highest on the
basis of survival time before death. Patients who
survived 12 months were ranked on the basis of
a favorable or unfavorable change in left ventricular mass (or physical-health composite score of
the RAND-36) from baseline to 12 months. We
right-censored (i.e., censoring when the event had
not yet occurred at the time of measurement)
patients at the time of transplantation or loss to
follow-up, so that patients who survived but did
not provide measurements of left ventricular mass
(or physical-health composite score) were included as 1-year survivors. We compared ranks between treatment groups with the use of the
log-rank test and calculated hazard ratios and
95% confidence intervals with the use of Cox
proportional-hazards regression. We prespecified
subgroup analyses according to sex, history or
no history of heart disease, anthropometric volume (volume calculated with the use of the Watn engl j med 363;24

son equation, <35 liters vs. ≥35 liters), duration
of end-stage renal disease (<4 years vs. ≥4 years),
and presence or absence of residual kidney function (defined as >100 ml of daily urine volume).
We analyzed the time to death or first hospitalization unrelated to vascular access using Cox
regression, and we used the Andersen–Gill method for the analysis of recurrent events. All analyses were performed according to the intentionto-treat principle. Analytic methods used for the
quantitative secondary outcomes are described
in the Supplementary Appendix. We performed
analyses of the main secondary outcomes without adjusting for multiple comparisons. Statistical analyses were performed with the use of SAS
software, version 9.2 (SAS Institute).

R e sult s
Study Population

Between January 1, 2006, and March 31, 2009, a
total of 378 patients were enrolled, and 245 underwent randomization (Fig. 1 in the Supplementary Appendix). As shown in Table 1, the base-
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Table 2. Features of Intervention.*

Variable

Conventional
Hemodialysis
(N = 120)

Frequent
Hemodialysis
(N = 125)

Ratio of Means
(Frequent vs.
Conventional)

P Value

2.88±0.39

5.17±1.11

1.80

<0.001

94.9

77.7

—

<0.001

3.4

8.0

—

Hemodialysis treatments per week (no.)
Expected treatments attended (% of patients)†
>80%
65–80%

14.4

—

Time per dialysis session (min)

<65%

213±28

1.7

154±25

0.72

<0.001
<0.001

Total dialysis time per week (hr)

10.4±1.6

12.7±2.2

1.23

Blood flow rate (ml/min)

402±41

396±42

0.99

0.26

Dialysate flow rate (ml/min)

710±106

747±68

1.05

0.001

Dialyzer urea clearance (ml/min)

269±22

271±21

1.01

0.47

Ultrafiltration
Per session (liters)

3.06±0.99

2.12±0.74

0.69

<0.001

Per session (% of weight after dialysis)

3.99±1.26

2.83±1.00

0.71

<0.001

Per week (liters)

8.99±3.03

10.58±3.83

1.18

<0.001

Kt/Vurea‡
Total weekly standard

2.57±0.26

3.60±0.57

1.40

<0.001

Dialysis weekly standard

2.49±0.27

3.54±0.56

1.42

<0.001

Equilibrated per session

1.41±0.21

1.06±0.21

0.75

<0.001

Before dialysis

58.4±13.8

46.5±14.4

0.80

<0.001

After dialysis

15.9±4.9

16.5±5.6

1.04

0.38

Blood urea nitrogen (mg/dl)§

* Plus–minus values are means ±SD. With the exception of number of treatments per week and treatments attended, all
treatment features were first averaged over each patient’s first modeled dialyses (sessions in which solutes are measured before and after the session) over each month of follow-up. Treatment attendance was monitored for all sessions
during the time that the patient remained under the care of investigators at the participating centers.
† Adherence rates of 65% and 80% represent an average of 1.95 and 2.40 treatments per week, respectively, in the conventional-hemodialysis group and 3.9 and 4.8 treatments per week, respectively, in the frequent-hemodialysis group.
‡ The weekly standard Kt/Vurea is defined as the ratio of the generation rate of urea to the average urea concentration before dialysis and is commonly used to compare small-molecule clearance among different methods and schedules of
dialysis.22 The dialysis weekly standard is the component of the total weekly standard Kt/Vurea that remains after correction for residual renal function.23 The equilibrated Kt/V (the ratio of the equilibrated urea clearance during each dialysis
session [Kt] to the patient’s urea distribution volume [V]) is computed with the use of a modified Tattersall correction
to single-pool Kt/V.17
§ To convert the values for blood urea nitrogen to millimoles per liter, multiply by 0.357.

line characteristics of the participants in the two
study groups were similar; the study population
was diverse with respect to age, sex, race or ethnic group, the primary cause of kidney disease,
coexisting conditions, income, and education; the
median duration of end-stage renal disease was
3.6 years (10th and 90th percentiles, 0.6 and 14.3).

patients who were assigned to undergo hemodialysis six times per week attended at least 80% of
the prescribed hemodialysis sessions. As expected, the per-session dialysis dose, ultrafiltration
volume, and weight gain between dialysis sessions were lower, and corresponding weekly values were higher, in the group that underwent
hemodialysis six times per week than in the group
Characteristics of the Study Intervention
that underwent the procedure three times per
Details of the characteristics of the intervention week. Figure 2 in the Supplementary Appendix
are provided in Table 2. A total of 78% of the shows the number of treatments per week, the
2292
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weekly treatment time, and the weekly standard23 hemodialysis group was 0.2±0.8 (P = 0.004) (Fig. 3
Kt/Vurea in both treatment groups.
in the Supplementary Appendix). Frequent hemodialysis was associated with significantly improved
Coprimary Outcomes
control of hypertension and hyperphosphatemia.
Five patients in the frequent-hemodialysis group Table 3 shows the baseline and 12-month results
died, as compared with 9 in the conventional- for the main secondary outcomes; standardized
hemodialysis group; 11 patients in the frequent- changes in the secondary outcome domains are
hemodialysis group underwent transplantation, shown in Figure 1C.
as compared with 13 in the conventional-hemodialysis group. Of the 5 patients in the frequent- Complications of Therapy
hemodialysis group who died, 4 died suddenly, As compared with patients in the conventionaland the fifth died from hemorrhage (from the vas- hemodialysis group, patients undergoing frequent
cular access). In the conventional-hemodialysis hemodialysis were more likely to undergo intergroup, 3 patients died suddenly, and 1 each died ventions related to vascular access, both in the
from myocardial infarction, stroke, sepsis, lung analysis of the time to the first intervention (hazcancer, hemorrhage (from the gastrointestinal ard ratio, 1.71; 95% CI, 1.08 to 2.73) (Fig. 4 in the
tract), and enterocolitis. Data on left ventricular Supplementary Appendix) and in the analysis of
mass at 12 months were missing for 22 patients, multiple interventions (hazard ratio, 1.35; 95% CI,
and data on baseline or 12-month RAND-36 phys- 0.84 to 2.18). There were 95 interventions related
ical-health composite scores were missing for 12 to vascular access (19 interventions to correct acpatients. Overall, the composite outcome of death cess failure and 76 other procedures) in the freor change in left ventricular mass was ascertained quent-hemodialysis group and 65 interventions
in 199 patients, and the composite outcome of (23 to correct access failure and 42 other procedeath or change in the RAND-36 physical-health dures) in the conventional-hemodialysis group;
composite score was ascertained in 211.
47% of the patients in the frequent-hemodialysis
Frequent hemodialysis was associated with fa- group underwent at least one procedure, as comvorable changes in both coprimary outcomes pared with 29% in the conventional-hemodialy(hazard ratio for death or increase in left ventricu- sis group. The percentages of events affecting
lar mass, 0.61; 95% confidence interval [CI], 0.46 fistulas, grafts, and catheters were 51%, 32%,
to 0.82; hazard ratio for death or a decrease in the and 17%, respectively, in the frequent-hemodialyRAND-36 physical-health composite score, 0.70; sis group and 48%, 38%, and 14%, respectively,
95% CI, 0.53 to 0.92) (Fig. 1A and 1B). The effects in the conventional-hemodialysis group.
The rates of adverse events are summarized
of frequent hemodialysis on the coprimary composite outcomes were not appreciably different in in Table 4. Episodes of hypotension during disubgroups according to sex, history or no history alysis in relation to the number of treatments
of heart disease, anthropometric volume, duration were less common in the frequent-hemodialysis
of end-stage renal disease, or presence or absence group than in the conventional-hemodialysis
group (10.9% vs. 13.6% of monitored sessions
of residual kidney function (data not shown).
with at least one recorded episode, P = 0.04).
Secondary Outcomes

There was no significant effect of frequent hemodialysis on the composite outcome of death or
hospitalization unrelated to vascular access (hazard ratio, 0.93; 95% CI, 0.62 to 1.39). The adjusted mean (±SE) left ventricular mass decreased by
16.4±2.9 g in patients in the frequent-hemodialysis group, as compared with 2.6±3.2 g in patients
in the conventional-hemodialysis group (P<0.001).
Patients in the frequent-hemodialysis group had
an increase in adjusted mean RAND-36 physicalhealth composite score of 3.4±0.8; the corresponding change in patients in the conventionaln engl j med 363;24

Discussion
In this multicenter, randomized trial of frequent,
as compared with conventional, in-center hemodialysis, we observed statistically significant and
clinically meaningful benefits with respect to
both coprimary composite end points — death or
12-month change in left ventricular mass and
death or 12-month change in self-reported physical health.
Our results extend those that have been shown
in several observational studies and clinical trials
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Patients with Better Outcome (%)

A Death or Change in LV Mass
100

100

80

80

60

60

40

40

Hazard ratio, 0.61 (95% CI, 0.46–0.82)
P<0.001

Frequent
hemodialysis

Conventional
hemodialysis
20

0

20

0

12

0

50

0

Survival (mo)

−50

−100

−150

Change in LV Mass among Survivors (g)

Patients with Better Outcome (%)

B Death or Change in PHC Score
100

100

80

80

60

60

40

40

20

20

0

0

12

Hazard ratio, 0.70 (95% CI, 0.53–0.92)
P=0.007

Conventional
hemodialysis
Frequent
hemodialysis

0

−15

Survival (mo)

0

15

30

Change in PHC Score among Survivors

C Main Secondary Outcomes
Outcome
LV mass
Physical-health composite score
Beck Depression Inventory score
Predialysis albumin
Predialysis phosphorus
ESA dose
Predialysis systolic blood pressure
Trail Making Test Part B
Death or hospitalization unrelated
to vascular access

Effect Measure

Estimated Standardized Effects (95% CI)

Mean decrease
Mean increase
Mean decrease
Mean increase
Mean decrease
Mean decrease in log
Mean decrease
Negative log relative risk
Negative log hazard ratio
−1.0

−0.5

0.0

0.5

1.0

Standard-Deviation Units
Conventional Better

comparing conventional and more frequent hemodialysis. DePalma et al.25 reported the initial
findings regarding an increased frequency of hemodialysis more than 40 years ago; in 1988,
Buoncristiani et al.26 found that control of hy2294
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Frequent Better

pertension and multiple metabolic factors were
improved when patients underwent hemodialysis
five to six times per week. Ting et al.27 showed
that among 42 patients who responded poorly to
conventional hemodialysis, frequent in-center he-
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Figure 1 (facing page). Coprimary Composite Outcomes
and Main Secondary Outcomes.
Kaplan–Meier curves are shown for the composite outcomes of death or change in left ventricular (LV) mass
(Panel A) and death or change in the physical-health
composite (PHC) score from the RAND 36-item health
survey (Panel B). For each value for the coprimary composite outcome on the horizontal axis, the Kaplan–
Meier curve indicates the proportion of patients in the
respective treatment groups with an equal or more favorable outcome. The horizontal distance between the
Kaplan–Meier curves at the 50% value on the vertical
axes indicates the median composite outcome results.
Median outcomes for the composite outcome of death
or change in LV mass correspond to a reduction in LV
mass of 12.3 g in the frequent-hemodialysis group, as
compared with a reduction of 2.2 g in the conventionaldialysis group (difference in medians, 10.1 g). The
greater separation in the two curves on the right side
of the graph of the change in LV mass is because nine
patients had reductions in LV mass of at least 60 g; all
of them were in the frequent-hemodialysis group. The
median results for the composite outcome of death or
change in physical-health composite score correspond
to an increase in the physical-health composite score
of 2 points in the frequent-hemodialysis group as compared with no change in the conventional-dialysis group
(difference in medians, 2 points). Changes in LV mass
ranged from a decrease of 51.2 g to an increase of 68.8 g
in the conventional-dialysis group and from a decrease
of 174.5 g to an increase of 61.9 g in the frequent-hemo
dialysis group. Changes in the physical-health composite score ranged from a decrease of 27 points to an increase of 22 points in conventional-dialysis group, and
from a decrease of 28 points to an increase of 29 points
in the frequent-hemodialysis group. The standardized
effect sizes for the main secondary outcomes (Panel C)
were calculated as follows: the mean differences in LV
mass, physical-health composite score (in which higher
scores indicate better physical health), Beck Depression
Inventory score (in which higher scores indicate more
severe depression), albumin concentration before dialysis, phosphorus concentration before dialysis, and systolic blood pressure before dialysis were divided by the
baseline standard deviation; the mean difference in log
dose of erythropoiesis-stimulating agent (ESA) was divided by the standard deviation of the log baseline ESA
dose; the log risk ratio for failure to complete the Trail
Making Test Part B was divided by square root ([1 – p]/p),
where p is the fraction of participants who did not complete the test within 5 minutes at baseline; the log hazard ratio for hospitalization unrelated to vascular access
or death was divided by square root (1/p), where p is
the fraction of patients with a hospitalization unrelated
to vascular access or death. ESA doses of less than
5000 erythropoietin equivalent units were set to 5000
before log transformation.

modialysis was associated with fewer days in the
hospital, improved health-related quality of life,
and improved control of hypertension and anemia. Ayus et al.28 compared 23 patients undern engl j med 363;24

going frequent in-center hemodialysis with 51
matched controls and found that patients undergoing frequent hemodialysis had a reduction
in left ventricular hypertrophy and lower concentrations of phosphate and C-reactive protein. Other
studies have examined the effects of frequent
home-based hemodialysis, often performed overnight (so-called nocturnal hemodialysis).29,30
Although these studies were pioneering, they
were limited by small sample sizes, inadequate or
no controls, selection bias, dropout bias, and an
emphasis on within-group, rather than betweengroup, inference tests. We elected not to allow
participants to perform frequent hemodialysis at
home, so that the benefits and risks of homebased therapies and the effects of session frequency could be disentangled.
In the conventional-hemodialysis group, the
prescribed dialysis dose was at or above the levels
recommended in clinical practice guidelines. In
both groups, other aspects of hemodialysis and
related care were standardized and monitored.
Given the excellent adherence to both treatment
regimens, the difference between the groups with
respect to solute clearance was maintained. The
vast majority of participants in the frequenthemodialysis group completed at least five sessions per week; participants in the conventionalhemodialysis group rarely had extra hemodialysis
sessions.
The trial met its prespecified criteria for showing overall benefit. The results of the FHN Daily
Trial can be compared with those of the HEMO
Study,12 in which 1846 patients were randomly
assigned to conventional or more intensive thriceweekly in-center hemodialysis. In the HEMO
Study, there was no overall effect on mortality,
the rate of hospitalization, or health-related quality of life among patients randomly assigned to
a target per-session equilibrated Kt/Vurea of 1.45
or 1.05, although subgroup analyses suggested a
possible benefit among women and a trend toward harm among men with the more intensive
treatment.31 It is possible that the benefit we
observed in the FHN trial among patients in the
frequent-hemodialysis group was due to an even
greater between-group difference with respect to
urea clearance, a marker of low-molecular-weight
solutes. Alternatively, the benefit of frequent
hemodialysis may result from improved control
of other metabolic by-products, such as phosphate or other retained uremic solutes, more
physiologic removal of solutes (yielding lower
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92

2.69±1.80

2.80±1.69

147±19

104

103

146±18

Conventional hemodialysis

53,093±63,552

1.82±1.73

2.58±1.68

137±19

147±18

56,176±102,288 41,877±44,636

57,070±65,456

93

Frequent hemodialysis

Antihypertensive agents consumed — no.

Frequent hemodialysis

Conventional hemodialysis

Weekly average predialysis systolic blood
pressure — mm Hg

90
103

Frequent hemodialysis

5.24±1.20

5.65±1.75

4.00±0.36

3.96±0.40

—
—

−0.23±1.35

−9.2±1.5

−9.7±18.2

−0.87±1.85

0.9±1.6

−18%±8%

0.9±16.2

−5%±10%

−3,976±69,525
−14,299±76,191

−0.08±0.14
−0.64±0.14

−0.03±1.54

0.01±0.03

−0.63±1.60

−0.02±0.03

−0.01±0.31

−2.0±0.7

−2.2±6.5
−0.02±0.36

−0.4±0.7

3.4±0.8

−0.2±7.7

3.3±8.9

0.2±0.8

−16.4±2.9

−16.3±35.3
0.1±8.7

−2.6±3.2

−2.4±25.9

—

−10.1 (−14.3 to −6.0)

−0.56 (−0.91 to −0.22)

0.02 (−0.06 to 0.10)

−1.6 (−3.4 to 0.3)

3.2 (1.0 to 5.4)

−13.8 (−21.8 to −5.8)

<0.001‡‡

<0.001

0.24

0.002

0.56

0.10

0.004

<0.001

P Value

of

Conventional hemodialysis

5.88±1.65

5.68±1.55

3.99±0.37

3.98±0.44

10.4±8.5

12.2±9.9

41.7±10.7

38.5±9.6

125±46

138±52

12 Months

Difference in Change
Change from Baseline Adjusted Mean (±SE) (Frequent–Conventional)
to 12 Months
Change from Baseline‡
(95% CI)

n e w e ng l a n d j o u r na l

Erythropoiesis-stimulating agents — EPO
equivalent units††

94
102

Conventional hemodialysis

Frequent hemodialysis

Predialysis phosphorus — mg/dl**

94
103

12.6±8.7

101

Frequent hemodialysis

12.4±9.0

38.4±11.0

38.5±9.3

88

Conventional hemodialysis

Predialysis albumin — g/dl

Frequent hemodialysis

Conventional hemodialysis

Beck Depression Inventory‖

93
104

142±59

101

Frequent hemodialysis

141±49

Baseline

84

No. with
Data†

Conventional hemodialysis

Physical-health composite score¶

Frequent hemodialysis

Conventional hemodialysis

Left ventricular mass — g§

Outcome

Table 3. Secondary Outcomes.*

The

m e dic i n e

december 9, 2010

The New England Journal of Medicine
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on July 29, 2014. For personal use only. No other uses without permission.
Copyright © 2010 Massachusetts Medical Society. All rights reserved.

125

48 (38.4)

46 (38.3)

23 (24.2)

19 (23.5)

12 Months

0.93 (0.62 to 1.39)

0.99 (0.81 to 1.21)

Risk Ratio (95% CI)

0.71

0.27‡‡

P Value

*		 Plus–minus values are means ±SD, except where noted otherwise. All the outcomes listed were prespecified main secondary outcomes except for weekly average systolic blood pressure before dialysis and number of antihypertensive agents consumed.
†		 For all outcomes except for death or hospitalization unrelated to vascular access, the number with data refers to the number of patients for whom both baseline and 12-month data
were available; for the outcome of death or hospitalization unrelated to vascular access, the number includes all patients who underwent randomization.
‡		 For all but the final three outcomes listed in the table, mixed-effects analyses were adjusted for the baseline level of the factor analyzed, presence or absence of diabetes, age, and
clinical center. The adjusted mean changes for erythropoiesis-stimulating agents indicate percent changes in geometric mean values from baseline to 1 year. Standard errors of the
adjusted means for erythropoiesis-stimulating agents were computed with the use of the delta method. The time to death or first hospitalization unrelated to vascular access was analyzed with the use of Cox regression, adjusted for presence or absence of diabetes, age, and clinical center. Additional details are provided in the Supplementary Appendix.
§		 When calculated per 1.73 m2 of body-surface area, the mean (±SD) left ventricular mass index at baseline was 131±46 g per 1.73 m2 in the conventional-hemodialysis group and
131±51 g per 1.73 m2 in the frequent-hemodialysis group. The estimated between-group difference in the change from baseline to 12 months (frequent hemodialysis − conventional
hemodialysis) was −12.5 g per 1.73 m2 (95% CI, −20.1 to −4.9).
¶		 The physical-health composite score was derived from the RAND 36-item health survey; scores range from 0 to 100, with higher scores indicating better health status.
‖		 Scores on the Beck Depression Inventory range from 0 to 63, with higher scores indicating more severe depression.
** To convert the values for phosphorus to millimoles per liter, multiply by 0.3229.
†† When darbepoetin was used, the dose levels were converted to the approximate equivalent erythropoietin (EPO) dose with the use of the following equation: EPO dose (in
units) = 250  ×  darbepoetin (in μg).24 The EPO (or equivalent transformed darbepoetin) dose was set to a minimum 5000 units per 4-week period for patients taking less than 5000
units and was log transformed before statistical analysis. From baseline to 12 months, the mean (±SD) hemoglobin level before dialysis decreased from 12.0±1.3 g per deciliter to
11.7±1.0 g per deciliter in the conventional-hemodialysis group, and remained stable at 12.0±1.2 g per deciliter and 12.0±0.9 g per deciliter at baseline and 12 months, respectively,
in the frequent-hemodialysis group. The estimated between-group difference in the change from baseline to 12 months (frequent hemodialysis − conventional hemodialysis) was
0.29 g per deciliter (95% CI, 0.02 to 0.55; P = 0.03).
‡‡ P values for the number of antihypertensive agents and the failure to complete the Trail Making Test Part B in 5 minutes were calculated with the use of exact Wilcoxon rank-sum
tests, stratified according to quartiles of the corresponding baseline values.

120

25 (26.3)

95

Frequent hemodialysis

22 (27.2)

Baseline

81

No. with
Data†

Conventional hemodialysis

Death or hospitalization unrelated to vascular
access — no. of patients (%)

Frequent hemodialysis

Conventional hemodialysis

Failure to complete Trail Making Test Part B
in 5 min — no. of patients (%)

Outcome
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Table 4. Adverse Events during the 12-Month Follow-up Period of the Study.*
Conventional Hemodialysis
(N = 120)

Outcome

no. of events
Death

Frequent Hemodialysis
(N = 125)

no. of patients
with event

no. of events

9

All hospitalizations

Hazard Ratio
(95% CI)

P Value

—

—

no. of patients
with event

5

114

47

109

58

0.88 (0.60–1.28)

0.50

Unrelated to vascular access

90

44

79

47

0.80 (0.53–1.21)

0.30

Related to vascular access

24

14

30

20

0.99 (0.54–1.82)

0.97

Cardiovascular-related

15

12

17

15

0.83 (0.44–1.59)

—

Infection related

27

20

27

23

0.83 (0.49–1.40)

—

65

29

95

47

1.35 (0.84–2.18)

0.22

23

15

19

15

0.71 (0.35–1.44)

0.35

All interventions related to vascular access
Correction of access failure
Other procedures

42

21

76

38

1.71 (0.98–2.97)

0.06

Episodes of hypotension†

470

87

724

99

—

—

Potassium <3.0 mmol/liter

0

0

0

0

—

—

Potassium <3.5 mmol/liter

6

5

13

8

—

0.57‡

9

7

15

9

—

0.80‡

Hypokalemia

Hypophosphatemia§

* The hazard ratios and P values for rates of events (including multiple events per patient) between the frequent-hemodialysis group and the
conventional-hemodialysis group were calculated with the use of the Andersen–Gill model, except where otherwise noted.
† The percentage of dialysis treatments with recorded hypotensive episodes, defined as the need for a lower ultrafiltration rate, reduced blood
flow, or saline administration to ameliorate hypotension, was 10.9% in the frequent-hemodialysis group and 13.6% in the conventional-
hemodialysis group (P = 0.04 with the use of generalized estimating equations).
‡ The P values for the comparison of the number of patients with at least one event of hypokalemia or hypophosphatemia were calculated
with the use of Fisher’s exact test.
§ Hypophosphatemia was defined as a phosphorus concentration of less than 2.17 mg per deciliter (0.7 mmol per liter).

and less variable time-averaged solute concentrations), or improved control of extracellular volume excess (reducing the time-averaged fluid
load). Consistently high weight gain between
dialysis sessions may induce hypertension, left
ventricular hypertrophy, and other adverse effects32-34; the lower weight gain between dialysis
sessions in the frequent-hemodialysis group may
be responsible for some of the benefit that we
observed with respect to left ventricular mass.
Although frequent hemodialysis is far from perfect, it may more closely approximate the capacity of a native or transplanted kidney to regulate
extracellular volume and solute composition.
However, the benefits of hemodialysis performed six times per week were gained at the
cost of more frequent interventions related to
vascular access. Although we cannot exclude the
possibility that these interventions were prompted by more frequent contact with the patient or
by providers’ fears, the fact that needle cannula2298
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tion of a fistula or graft or manipulation of a
catheter occurred approximately twice as frequently in the frequent-hemodialysis group as in
the conventional-dialysis group could have contributed directly to the complications we observed.
The study has several strengths, including its
relatively large sample size, the use of cardiac MRI
for the assessment of left ventricular mass, the
diversity of the study population, high adherence
rates, and the wide array of outcomes linked to
death and complications among patients with endstage renal disease.35,36 The study also has several
important limitations. Owing to feasibility and
other logistic concerns, the sample size was insufficient to determine the effects of frequent in-center hemodialysis on death, cause-specific death,
hospitalization, or other events. Although we determined a priori that favorable effects on both
coprimary composite outcomes would be required
in order to consider the trial to have had positive
results, the rate of death in both groups was low,
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and the bulk of the treatment effect was seen in
intermediate outcomes. Studies involving patients
with37 and patients without38 end-stage renal disease have suggested that treatments targeted to
reducing left ventricular mass are associated with
lower rates of death and cardiovascular events. In
observational analyses, differences in left ventricular mass33 and self-reported physical health39 of
lesser magnitude than those shown in our study
have been associated with significantly improved
outcomes in this population. We excluded patients
who had ample residual kidney function and patients who were not expected to survive for more
than 6 months; we cannot generalize the study’s
results to these large and important segments of
the population undergoing hemodialysis. To limit
the risk of the “false discovery” of multiple effects,
we designated a single outcome for each domain
as a key secondary outcome (except in the case of
hypertension, for which we specified two main
secondary outcomes). These designations were
somewhat arbitrary.
In summary, as compared with conventional
hemodialysis, frequent hemodialysis was associated with favorable changes in the composite

coprimary outcomes of death or 12-month change
in left ventricular mass and death or 12-month
change in the RAND-36 physical-health composite score. Frequent hemodialysis improved the
control of hypertension and hyperphosphatemia
but had no significant effects on cognitive performance, self-reported depression, serum albumin concentration, or use of erythropoiesis-stimulating agents. Patients who underwent frequent
hemodialysis were significantly more likely to
undergo interventions related to vascular access.
Before major changes in practice can be recommended, the net effects of frequent hemodialysis
will need to be balanced against the added burden for the patient and societal cost.
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